Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 57%
Buy 36%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. demonstrates a strong position in the biotechnology sector, driven by the success of its RLY-2608 candidate, which has shown a notable Overall Response Rate (ORR) of 67% in patients with kinase mutations, alongside an improvement in median progression-free survival (mPFS) to 11.4 months. The favorable clinical results, particularly for RLY-2608 in combination with existing therapies such as Faslodex, underscore the company's innovative approach to precision oncology and the therapeutic potential of its pipeline. Furthermore, with anticipated cash reserves of $781 million to support ongoing trials, Relay Therapeutics is well-positioned to navigate future developments and address investor concerns about trial scale and dosing, contributing to an optimistic outlook for the stock.

Bears say

Relay Therapeutics Inc. is facing a challenging financial outlook, projecting a full-year net loss of $2.15 per share for 2025, which reflects ongoing concerns about its clinical development pathways and operational performance. The company is at risk from multiple factors, including potential negative clinical data, regulatory approval failures, and competitive landscape threats, all of which could hinder the advancement of its drug candidates like RLY-4008 and RLY-2608. Furthermore, projected losses for 2024 were recorded at $2.36 per share, aligning closely with initial estimates, indicating persistent financial strain without any immediate signs of turnaround.

RLAY has been analyzed by 14 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 36% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 14 analysts, RLAY has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.